Cancer Center– A Cancer Center Designated by
the National Cancer Institute
Profile http://oncology.stanford.edu/profiles/cancer/faculty/Branimir_Sikic/ Email this pagePrinter friendly version
View Larger

Key Documents

Branimir I. Sikic, M. D.

Academic Appointments

Contact Information

  • Clinical Offices
    Medical Oncology 875 Blake Wilbur Dr Clinic B MC 5820 Stanford, CA 94305-5820
    Tel Work (650) 498-6000 Fax (650) 725-9113
  • Academic Offices
    Administrative Contact
    Carla Edwards Administrative Assistant Tel Work 650-723-5290
    Not for medical emergencies or patient use

Professional Snapshot

Clinical Focus

  • Cancer > Medical Oncology
  • Cancer > Non-Hematologic Cancers
  • Medical Oncology
  • New Drug Studies

Administrative Appointments

  • Associate Director, Stanford Cancer Center (2009 - present)
  • Co-Director, Stanford Center for Clinical and Translational Education and Research, Stanford University (2008 - present)
  • Director, Clinical and Translational Research Unit, Stanford University (2008 - present)
  • Chairman, Annual Northern California Tumor Board at Silverado, Stanford University School of Medicine (1999 - present)
  • Scientific Program Committee Chair, American Society of Clinical Oncology (2005 - 2006)

Honors and Awards

  • John H. Blaffer Visiting Professor, M.D. Anderson Cancer Center (2003)
  • Best Doctors in America, "Best Doctors" annual survey (2002-08)
  • Oncology Teaching Award, Oncology Division, Stanford (2000)
  • Plenary lecturer in drug resistanc e, Netherlands Cancer Institute (1999)
  • 70th Anniversary of the CRC lecture, British Association of Cancer Research (1993)
View all 6honors and awards of Branimir Sikic

Professional Education

Board Certification: Medical Oncology, American Board of Internal Medicine (1979)
Fellowship: Georgetown University Hospital, DC (1979)
Fellowship: National Cancer Institute, MD (1978)
Board Certification: Internal Medicine, American Board of Internal Medicine (1975)
Residency: Georgetown University Hospital, DC (1975)
View All 9

Postdoctoral Advisees

Francois Moisan

Graduate & Fellowship Program Affiliations

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Consulting:Kanisa
Equity:Kanisa

Scientific Focus

Research Interests

Our goals are to understand mechanisms of drug resistance in cancer cells and to develop more effective therapies. Current research ranges from biochemical and molecular studies in cellular models to Phase I, II and III clinical trials of new inhibitors of drug resistance and novel therapies such as multi-targeted tyrosine kinase inhibitors and activators of TRAIL signaling. We are developing approaches to personalized therapies of ovarian cancer using biomarkers to select individualized treatments for patients.

Laboratory projects include studies of the multidrug transporter P-glycoprotein, regulation of the MDR1 gene, the role of beta tubulin gene expression in resistance to taxanes and vinca alkaloids, and the use of gene expression profiling in discovering molecular and genetic determinants of outcomes in cancer treatment in various cancers, particularly ovarian, colorectal, and acute myeloid leukemias.

Clinical investigations include the prognostic significance of resistance gene expression in cancers, pharmacokinetic consequences of MDR modulation, development of new modulators of drug resistance, and new targeted drugs, including kinase inhibitors and inhibitors of apoptosis. We are performing pharmacogenetic and pharmacogenomic studies to investigate determinants of response and toxicities in these patients.

Stanford Medicine Resources:

Footer Links: